- Our Story
- Our Products
- Our Science
- Our People & Citizenship
-
Investors
- Reports and Filings
- Presentations & Earnings Calls
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Details of Shares for transfer to IEPF May 2021
- Notice pursuant to IEPF Rules, May 2021
- Governance
- Investor Services
-
ESG profile
- Media
- Partners
- Contact Us
Dr. Reddy's in the news
-
Sustainability is mandatory for business survival
Dr Reddy’s Laboratories is a leader in more ways than one. The company has a lesser-known distinction of being the first pharma company in India to publish a sustainability report.
Click Here for the Complete Story [PDF Format] -
Helping hand of a medicine
Just what constitutes the idea of a Corporate Citizen? Is it a company's CSR (corporate social responsibility) initiatives or does it entail an ethical way of doing business... And the honour went to Dr Reddy's Foundation (DRF), the CSR arm of Dr Reddy's
Click Here for the Complete Story [PDF Format] -
Dr. Reddy's Mode of Discovery
The Indian drugmaker's CEO explains the company's move from generic offerings, and its intent on securing a spot among the world's top 25 pharma companies.
Click Here for the Complete Story [PDF Format] -
Top 20 Life Sciences Institutes of India
Being the most cost effective and compliant contract manufacturing hub (for pharmaceuticals) in Asia, Indian CMO's are now becoming more innovative, diversified and are adopting state-of-the-art process technology and international standards to stay compe
Click Here for the Complete Story [PDF Format] -
Dr. Reddy's aims to be a Biosimilar leader
Hyderabad-based, Dr. Reddy's Laboratories, the $1.2 billion Indian Pharma major, and one of the world's leading generics players, is making determined efforts to increase its portfolio of biosimilar products and become a global leader in the next decade i
Click Here for the Complete Story [PDF Format] -
Meet Anji Reddy, The Philanthropist
The Chairman of Dr. Reddy's Labs is morphing into one of India's most committed givers. Dr. Reddy's eponymous founder in now attacking social problems.
Click Here for the Complete Story [PDF Format] -
Generic Drug Manufacturer's Supply Chain
Triple-digit growth rates, regulatory issues and the highly competitive nature of the generic drug market posed complexity issues for this India-based pharmaceutical company. UPS Supply Chain Solutions helped Dr. Reddy's sort it all out.
Click Here for the Complete Story [PDF Format] -
Trials by Fire
Pharma entrepreneurs like Ajay Piramal and Anji Reddy are betting on drug discovery to double the industry's value to $129 billion by 2015.
Click Here for the Complete Story [PDF Format]
